Spring Bioscience offers
Rabbit Monoclonal PTEN (SP218)
antibody optimized for IHC
September 2013
Spring's PTEN (SP218) recombinant rabbit monoclonal primary antibody is a highly sensitive and specific clone that provides researches and pathologists with a clean, specific and sensitive IHC signal to confidently assess PTEN loss while minimizing background or non-specific staining. SP218 can provide researches and pathologists a more accurate interpretation for PTEN status.
Click here for product details.
Advantages of rabbit monoclonal anti-PTEN (SP218) from Spring Bioscience: 
  • Highly sensitive and specific monoclonal antibody
  • Robust performance for FFPE tissue
  • Minimized background and non-specific staining
  • Increased accuracy for PTEN status interpretation
Overview of comparison testing, showing variations in specificity and sensitivity among SP218 and competitive anti-PTEN antibodies on prostate and colon samples
Interpretation of PTEN loss using SP218 can provide pathologists a more accurate assessment of PTEN protein expression



Cancer cells from prostate adenocarcinoma (panel A) and colon adenocarcinoma (panel D) show total loss or diminished expression of PTEN when SP218 is used. In contrast, nuclear staining (panel B and C, arrows) in cancer cells is present for clones D4.3 and 138G6. Diffuse cytoplasmic and stromal staining are prominent for clones D4.3 and 138G6. But interestingly, the stromal cell components (fibroblasts, lymphocytes, and endothelial cells) are stained with similar intensities across all images. This suggests that there is non-specific staining in stromal and cancer area with the CST clones (D4.3 and138G6) when compared with the Spring clone.
Above: Human colon adenocarcinoma stained with PTEN (SP218) recombinant rabbit monoclonal primary antibody
Comparison Study

Click here for poster presentation